Exploratory analysis of biomarkers associated with clinical outcomes from the study of palbociclib plus endocrine therapy in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer
-
Published:2022-04
Issue:
Volume:62
Page:52-60
-
ISSN:0960-9776
-
Container-title:The Breast
-
language:en
-
Short-container-title:The Breast
Author:
Lee SoohyeonORCID,
Park KyungheeORCID,
Kim Gun Min,
Jung Kyung HaeORCID,
Kang Seok Yun,
Park In Hae,
Kim Jee Hyun,
Ahn Hee KyungORCID,
Park Woong-Yang,
Im Seock-Ah,
Park Yeon HeeORCID
Subject
General Medicine,Surgery
Reference21 articles.
1. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
2. Palbociclib and letrozole in advanced breast cancer;Finn;N Engl J Med,2016
3. Overall survival with ribociclib plus endocrine therapy in breast cancer;Im;N Engl J Med,2019
4. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer;Hortobagyi;Ann Oncol,2019
5. The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy-MONARCH 2: a randomized clinical trial;Sledge;JAMA Oncol,2020
Cited by
14 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献